Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Groupement Radiothérapie Hématologie Oncologie from Brussel, company number BE0452611502, closed financial year 2025 with a result of € -248,159 after tax. For that financial year Groupement Radiothérapie Hématologie Oncologie recorded a gross margin of € -237,086 and equity of € 1.4 million. Compared with financial year 2024, the result moved from € -28,586 to € -248,159. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 1.4 million
▼ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -248,159
▼ 768 % more loss than in 2024
Profit after tax over the fiscal year.
€ 804,157
▼ 13% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 13,881
▼ 37% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,785
▲ € 2,263 vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -90,709 | € -218,285 | € -19,307 | € -237,086 | ▼ € 217,779 |
| Profit after taxes | € -93,163 | € -229,251 | € -28,586 | € -248,159 | ▼ € 219,574 |
| Equity | € 1,861,640 | € 1,632,388 | € 1,603,802 | € 1,355,643 | ▼ 15% |
| Total debts | € 112 | € 7,569 | € 522 | € 22,785 | ▲ € 22,263 |
| Cash | € 966,588 | € 761,171 | € 922,013 | € 804,157 | ▼ 13% |
| Retained profit | € 1,861,640 | € 1,632,388 | € 1,603,802 | € 1,355,643 | ▼ 15% |
| Bank debt | € 0 | € 5,759 | € 0 | € 0 | |
| Balance sheet total | € 1,861,752 | € 1,639,957 | € 1,604,324 | € 1,378,428 | ▼ 14% |
Key figures of Groupement Radiothérapie Hématologie Oncologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Groupement Radiothérapie Hématologie Oncologie?
What happened at Groupement Radiothérapie Hématologie Oncologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 248,159. Source: NBB ↗
- Start of the company according to the CBE. KBO
In short
From € 93,163 loss in 2022 to € 248,159 loss in 2025.
A new publication or filing at Groupement Radiothérapie Hématologie Oncologie? We notify you, reason included.
Follow Groupement Radiothérapie Hématologie OncologieDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Groupement Radiothérapie Hématologie Oncologie are Deborah BAUWENS, Sabine MARICHAL and Sophie CVILIC. Sabine MARICHAL is also behind DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ.
Directors
According to the 2025 annual accounts
Deborah BAUWENS
Director
Sophie CVILIC
Director
Establishments
Establishment units
Physical locations of this company
Kruidtuinlaan 32
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Kliniek Sint-Jan
€ 233.8 million revenue · 2025
NEURO SAINT - JEAN
SERVICE D'ANESTHESIOLOGIE
€ -6,876 gross margin · 2025
PALIATIEVE ZORGEN SINT JAN - SOINS PALLIATIFS SAINT JEAN
OB - GYN ST. JEAN
€ 8,262 gross margin · 2025
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0452.611.502
- VAT number
- BE 0452.611.502
- Registered office
- Kruidtuinlaan 32, 1000 Brussel
- Names & denominations
- Groupement Radiothérapie Hématologie Oncologie · R.H.O.
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 17 March 1994
- Peppol
- Not registered
- Activities · NACE
Activiteiten van algemene ziekenhuizen, muv geriatrische en gespecialiseerde ziekenhuizen
Ziekenhuizen